Breast Cancer
The study design is described as an ongoing phase 3 clinical study of tucatinib plus ado-trastuzumab emtansine (T-DM1) in patients with unresectable locally advanced or metastatic HER2+ breast cancer. Read More ›
OS (overall survival) data favored margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in patients with metastatic breast cancer (MBC) in the SOPHIA study; however, the data did not reach statistical significance at a second interim analysis after 270 events. Read More ›
The ATEMPT trial results demonstrated that in patients with stage I HER2+ breast cancer, adjuvant trastuzumab emtansine monotherapy failed to demonstrate the prespecified reduction in clinically relevant toxicities compared with trastuzumab. Read More ›
ARX788, an antibody-drug conjugate of anti-HER2 monoclonal antibody linked to a tubulin inhibitor, was shown to be well tolerated in heavily pretreated patients with HER2+ metastatic breast cancer, without evidence of grade ≥3 pneumonitis, and an encouraging overall response rate in the 1.3-mg/kg every-3-weeks cohort. Read More ›
The combination of ruxolitinib and trastuzumab without chemotherapy was well tolerated but failed to demonstrate improved progression-free survival compared with historical controls in patients with HER2+ metastatic breast cancer. Read More ›
Results of the phase 3 HER2CLIMB study show that in patients with HER2+ metastatic breast cancer with and without brain metastases, the combination of tucatinib with capecitabine and trastuzumab significantly improves survival and could become a new standard of care. Read More ›
Preclinical data demonstrated that tucatinib potentiates the activity of T-DM1 in HER2+ breast cancer models in vitro and in vivo, and enhances the activity of a camptothecin-based HER2 antibody-drug conjugate comprised of trastuzumab conjugated with 8 exatecan moieties. Read More ›
Shanu Modi, MD, provided an overview of promising novel therapies in development for the treatment of refractory HER2+ metastatic breast cancer. Read More ›
Results from the phase 2 PATRICIA study suggest pertuzumab plus high-dose trastuzumab may have clinical utility in some patients with HER2+ metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases. Read More ›
Results from the MetaPHER study showed the safety profile of first-line subcutaneous trastuzumab + intravenous (IV) pertuzumab and IV docetaxel for HER2+ advanced breast cancer was consistent with the known safety profile and efficacy data reported for IV trastuzumab + IV pertuzumab and IV docetaxel. Read More ›